Influenza virus host response of C57BI/6 mice treated with TACI-Ig

Immunopharmacology and Immunotoxicology

Volumn 28, Issue 1, 2006, Pages 13-32

  Roque, R ^a   Ponce, R ^a   Burleson, F ^b   Cabrit, M ^c   Broly, H ^c   Rogge, M ^a  

^a ZYMOGENETICS INC   (United States)

^b BRT Burleson Research Technologies Inc   (United States)

^c Serono International SA   (Switzerland)

Author keywords

Influenza; Mouse; TACI Ig

Indexed keywords

APRIL PROTEIN; CORTICOSTEROID; DEXAMETHASONE; GLYCOPROTEIN; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN M; RECOMBINANT PROTEIN; TRANSMEMBRANE ACTIVATOR AND CAML INTERACTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOPSY; B LYMPHOCYTE; BODY WEIGHT; CELLULAR IMMUNITY; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HOST RESISTANCE; IMMUNE RESPONSE; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOPHENOTYPING; INFLUENZA; INFLUENZA VIRUS; LUNG; MALE; MOUSE; NONHUMAN; ORGAN WEIGHT; PRIORITY JOURNAL; SPLEEN WEIGHT; SURVIVAL RATE; VIRUS INFECTION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIBODY SPECIFICITY; BODY WEIGHT; DEXAMETHASONE; EXCIPIENTS; FEMALE; HUMANS; IMMUNOGLOBULIN FC FRAGMENTS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INFLUENZA A VIRUS, H3N2 SUBTYPE; LUNG; MALE; MEMBRANE PROTEINS; MICE; NEUTRALIZATION TESTS; ORGAN SIZE; ORTHOMYXOVIRIDAE INFECTIONS; PHENOTYPE; RECEPTORS, TUMOR NECROSIS FACTOR; SURVIVAL ANALYSIS; TRANSMEMBRANE ACTIVATOR AND CAML INTERACTOR PROTEIN; VEHICLES;

ANIMALIA; ORTHOMYXOVIRIDAE; PRIMATES;

EID: 33646705898     PISSN: 08923973     EISSN: 15322513     Source Type: Journal    
DOI: 10.1080/08923970600623541     Document Type: Article

References (35)

1. Moore, P.A.; Belvedere, O.; Orr, A.; Fieri, K.; LaFleur, D.W.; Feng, P.; Soppet, D.; Charters, M.; Gentz, R.; Parmelee, D.; Li, Y.; Galperina, O.; Giri, J.; Roschke, V.; Nardelli, B.; Carrell, J.; Sosnovtseva, S.; Greenfield, W.; Ruben, S.M.; Olsen, H.S.; Fikes, J., and Hilbert, D.M. BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science. 1999, 285, 260-263.
2. Dillon, S.R.; Gross, J.A.; Ansell, S.M., and Novak, A.J. An APRIL to remember: novel TNF ligands as therapeutic targets. Nature Reviews Drug Discovery. 2006, 5, 235-246.
3. Stohl, W. A therapeutic role for BLyS antagonists. Lupus. 2004, 13, 317-322.
4. Koyama, T.; Tsukamoto, H.; Miyagi, Y.; Himeji, D.; Otsuka, J.; Miyagawa, H.; Harada, M., and Horiuchi, T. Raised serum APRIL levels in patients with systemic lupus erythematosus. Ann. Rheum. Dis. 2005, 64, 1065-1067.
5. Tan, S.M.; Xu, D.; Roschke, V.; Perry, J.W.; Arkfeld, D.G.; Ehresmann, G.R.; Migone, T.S.; Hilbert, D.M., and Stohl, W. Local production of B lymphocyte stimulator protein and APRIL in arthritic joints of patients with inflammatory arthritis. Arthritis Rheum. 2003, 48, 982-992.
6. Cheema, G.S.; Roschke, V.; Hilbert, D.M., and Stohl, W. Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis Rheum. 2001, 44, 1313-1319.
7. Novak, A.J.; Darce, J.R.; Arendt, B.K.; Harder, B.; Henderson, K.; Kindsvogel, W.; Gross, J.A.; Greipp, P.R., and Jelinek, D.F. Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival. Blood. 2004, 103, 689-694.
8. Moreaux, J.; Legouffe, E.; Jourdan, E.; Quittet, P.; Reme, T.; Lugagne, C.; Moine, P.; Rossi, J.F.; Klein, B., and Tarte, K. BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone. Blood. 2004, 103, 3148-3157.
9. Gross, J.A.; Johnston, J.; Mudri, S.; Enselman, R.; Dillon, S.R.; Madden, K.; Xu, W.; Parrish-Novak, J.; Foster, D.; Lofton-Day, C.; Moore, M.; Littau, A.; Grossman, A.; Haugen, H.; Foley, K.; Blumberg, H.; Harrison, K.; Kindsvogel, W., and Clegg, C.H. TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature. 2000, 404, 995-999.
10. Gross, J.A.; Dillon, S.R.; Mudri, S.; Johnston, J.; Littau, A.; Roque, R.; Rixon, M.; Schou, O.; Foley, K.P.; Haugen, H.; McMillen, S.; Waggie, K.; Schreckhise, R.W.; Shoemaker, K.; Vu, T.; Moore, M.; Grossman, A., and Clegg, C.H. TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease, impaired B cell maturation in mice lacking BLyS. Immunity. 2001, 15, 289-302.
11. Stein, J.V.; Lopez-Fraga, M.; Elustondo, F.A.; Carvalho-Pinto, C.E.; Rodriguez, D.; Gomez-Caro, R.; De Jong, J.; Martinez, A.C.; Medema, J.P., and Hahne, M. APRIL modulates B and T cell immunity. J. Clin. Invest. 2002, 109, 1587-1598.
12. Varfolomeev, E.; Kischkel, F.; Martin, F.; Seshasayee, D.; Wang, H.; Lawrence, D.; Olsson, C.; Tom, L.; Erickson, S.; French, D.; Schow, P.; Grewal, I.S., and Ashkenazi, A. APRIL-deficient mice have normal immune system development. Mol. Cell. Biol. 2004, 24, 997-1006.
13. Castigli, E.; Scott, S.; Dedeoglu, F.; Bryce, P.; Jabara, H.; Bhan, A.K.; Mizoguchi, E., and Geha, R.S. Impaired IgA class switching in APRIL-deficient mice. Proc. Natl. Acad. Sci. USA 2004, 101, 3903-3908.
14. Mackay, F.; Schneider, P.; Rennert, P., and Browning, J. BAFF AND APRIL: a tutorial on B cell survival. Annu. Rev. Immunol. 2003, 21, 231-264.
15. Do, R.K.; Hatada, E.; Lee, H.; Tourigny, M.R.; Hilbert, D., and Chen-Kiang, S. Attenuation of apoptosis underlies B lymphocyte stimulator enhancement of humoral immune response. J. Exp. Med. 2000, 192, 953-964.
16. Nardelli, B.; Belvedere, O.; Roschke, V.; Moore, P.A.; Olsen, H.S.; Migone, T.S.; Sosnovtseva, S.; Carrell, J.A.; Feng, P.; Giri, J.G., and Hilbert, D.M. Synthesis and release of B-lymphocyte stimulator from myeloid cells. Blood. 2001, 97, 198-204.
17. Litinskiy, M.B.; Nardelli, B.; Hilbert, D.M.; He, B.; Schaffer, A.; Casali, P., and Cerutti, A. DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL. Nat. Immunol. 2002, 3, 822-829.
18. Baker, K.P. BLyS - an essential survival factor for B cells: basic biology, links to pathology and therapeutic target. Autoimmun. Rev. 2004, 3, 368-375.
19. Amanna, I.J.; Dingwall, J.P., and Hayes, C.E. Enforced bcl-xL gene expression restored splenic B lymphocyte development in BAFF-R mutant mice. J. Immunol. 2003, 170, 4593-4600.
20. Avery, D.T.; Kalled, S.L.; Ellyard, J.I.; Ambrose, C.; Bixler, S.A.; Thien, M.; Brink, R.; Mackay, F.; Hodgkin, P.D., and Tangye, S.G. BAFF selectively enhances the survival of plasmablasts generated from human memory B cells. J Clin. Invest. 2003, 112, 286-297.
21. Owens, S.L.; Osebold, J.W., and Zee, Y.C. Dynamics of B-lymphocytes in the lungs of mice exposed to aerosolized influenza virus. Infect. Immun. 1981, 33, 231-238.
22. Gerhard, W. The role of the antibody response in influenza virus infection. Curr. Top. Microbiol. Immunol. 2001, 260, 171-190.
23. Burleson, G.R., Pulmonary immunocompetence and pulmonary immunotoxicology, in Experimental Immunotoxicology, R. Smialowicz and M.P. Holsapple, Editors. 1996, CRC Press, Inc.: Boca Raton, Florida. p. 113-135.
24. Burleson, G.R., Influenza virus host resistance model for assessment of immunotoxicity, immunostimulation, and antiviral compounds. In: Methods in immunotoxicology, G.R. Burleson, J.H. Dean, and A.E. Munson, Editors. 1995, Wiley-Liss, Inc.: New York, N.Y. p. 181-202.
25. Lebrec, H.; Sarlo, K., and Burleson, G.R. Effect of influenza virus infection on ovalbumin-specific IgE responses to inhaled antigen in the rat. J. Toxicol. Environ. Health. 1996, 49, 619-630.
26. Burleson, G.R. Models of respiratory immunotoxicology and host resistance. Immunopharmacology. 2000, 48, 315-318.
27. Burleson, G.R.; Lebrec, H.; Yang, Y.G.; Ibanes, J.D.; Pennington, K.N., and Birnbaum, L.S. Effect of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) on influenza virus host resistance in mice. Fundam. Appl. Toxicol. 1996, 29, 40-47.
28. Lebrec, H., and Burleson, G.R. Influenza virus host resistance models in mice and rats: utilization for immune function assessment and immunotoxicology. Toxicology. 1994, 91, 179-188.
29. Sedger, L.M.; Hou, S.; Osvath, S.R.; Glaccum, M.B.; Peschon, J.J.; van Rooijen, N., and Hyland, L. Bone marrow B cell apoptosis during in vivo influenza virus infection requires TNF-alpha and lymphotoxin-alpha. J. Immunol. 2002, 169, 6193-6201.
30. Lohman, B.L. and Welsh, R.M. Apoptotic regulation of T cells and absence of immune deficiency in virus-infected gamma interferon receptor knockout mice. J. Virol. 1998, 72, 7815-7821.
31. Ely, K.H.; Cauley, L.S.; Roberts, A.D.; Brennan, J.W.; Cookenham, T., and Woodland, D.L. Nonspecific recruitment of memory CD8+ T cells to the lung airways during respiratory virus infections. J. Immunol. 2003, 170, 1423-1429.
32. Woodland, D.L.; Hogan, R.J., and Zhong, W. Cellular immunity and memory to respiratory virus infections. Immunol. Res. 2001, 24, 53-67.
33. Lebrec, H.; Roger, R.; Blot, C.; Burleson, G.R.; Bohuon, C., and Pallardy, M. Immunotoxicological investigation using pharmaceutical drugs. In vitro evaluation of immune effects using rodent or human immune cells. Toxicology. 1995, 96, 147-156.
34. Topham, D.J.; Tripp, R.A.; Hamilton-Easton, A.M.; Sarawar, S.R., and Doherty, P.C. Quantitative analysis of the influenza virus-specific CD4 + T cell memory in the absence of B cells and Ig. J. Immunol. 1996, 157, 2947-2952.
35. Harada, Y.; Muramatsu, M.; Shibata, T.; Honjo, T., and Kuroda, K. Unmutated immunoglobulin M can protect mice from death by influenza virus infection. J. Exp. Med. 2003, 197, 1779-1785.